ABOUT MANCHESTER: University of Manchester spin-out Gelmetix raises £1.2m to develop back pain treatment

Description

Professor Tony Freemont, Director of MMPathIC (Manchester Molecular Pathology Innovation Centre), an MRC/EPSRC Molecular Pathology node funded with £2.9M to translate novel medical technology discoveries into use within the NHS, and Founder and Board Member of Gelexir, has hailed the treatment’s potential significance for back pain and OA sufferers.

He said: “It has taken nearly 15 years of basic research and translational development to reach this point. It is so exciting to see this completely novel approach to treatment pass through all the regulatory processes and reach a point where we can evaluate it in patients with debilitating back pain, for whom there is no other hope for pain relief. The development of this product, and the work of MMPathIC are just two ways in which The University of Manchester is working towards improving patient lives through research.”